Spectrum Pharmaceuticals (SPPI) PT Lowered to $4 at JMP Securities, After Receiving FDA CRL
Tweet
Share
E-mail
Get Alerts SPPI Hot Sheet
Price: $1.03 --0%
Rating Summary:
3 Buy, 6 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Rating Summary:
3 Buy, 6 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Join SI Premium – FREE
JMP Securities analyst Reni J. Benjamin lowered the price target on Spectrum Pharmaceuticals (NASDAQ: SPPI) to $4.00 (from $12.00) while maintaining a Market Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Upgrades Plains GP Holdings, L.P (PAGP) to Neutral
- Meituan Dianping (3690:HK) (MPNGF) PT Lowered to HK$93 at Macquarie
- Seiko Group Corp (8050:JP) PT Raised to JPY7,400 at Nomura/Instinet
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
JMP Securities, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
